Unknown

Dataset Information

0

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.


ABSTRACT: To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML).We randomly assigned 2,157 patients (age range, 15 to 60 years) to receive intensive induction-consolidation chemotherapy containing either daunorubicin, idarubicin, or mitoxantrone. After achieving complete remission (CR), patients were assigned to undergo either allogeneic or autologous stem-cell transplantation (SCT), depending on the availability of a sibling donor.The overall CR rate (69%) was similar in the three groups. Autologous SCT was performed in 37% of cases in the daunorubicin arm versus only 29% and 31% in mitoxantrone and idarubicin, respectively (P < .001). However, the disease-free survival (DFS) and survival from CR were significantly shorter in the daunorubicin arm: the 5-year DFS was 29% versus 37% and 37% in mitoxantrone and idarubicin, respectively. The proportion of patients who underwent allogeneic SCT (22%) was equivalent in the three treatment groups, and the outcome was similar as well. The [corrected] 5-year overall survival rates were 31%, 34%, and 34%, [corrected] respectively.In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy.

SUBMITTER: Mandelli F 

PROVIDER: S-EPMC2773224 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

Mandelli Franco F   Vignetti Marco M   Suciu Stefan S   Stasi Roberto R   Petti Maria-Concetta MC   Meloni Giovanna G   Muus Petra P   Marmont Filippo F   Marie Jean-Pierre JP   Labar Boris B   Thomas Xavier X   Di Raimondo Francesco F   Willemze Roel R   Liso Vincenzo V   Ferrara Felicetto F   Baila Liliana L   Fazi Paola P   Zittoun Robert R   Amadori Sergio S   de Witte Theo T  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091013 32


<h4>Purpose</h4>To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML).<h4>Patients and methods</h4>We randomly assigned 2,157 patients (age range, 15 to 60 years) to receive intensive induction-consolidation chemotherapy containing either daunorubicin, idarubicin, or mitoxantrone. After achieving complete remission (CR), patients were assigned to undergo either allogenei  ...[more]

Similar Datasets

| S-EPMC7334867 | biostudies-literature
| S-EPMC4604495 | biostudies-literature
| S-EPMC7697114 | biostudies-literature
| S-EPMC3260002 | biostudies-literature
| S-EPMC4807422 | biostudies-literature
| S-EPMC3148280 | biostudies-literature
| S-EPMC10590325 | biostudies-literature
| S-EPMC2864316 | biostudies-literature
| S-EPMC4317248 | biostudies-literature